Edmond DE Rothschild Holding S.A. Has $634,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Edmond DE Rothschild Holding S.A. raised its position in shares of Amgen Inc. (NASDAQ:AMGN) by 63.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,230 shares of the medical research company’s stock after buying an additional 866 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Amgen were worth $634,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. MAI Capital Management raised its position in Amgen by 17.8% in the 1st quarter. MAI Capital Management now owns 45,774 shares of the medical research company’s stock worth $13,014,000 after purchasing an additional 6,933 shares during the last quarter. Sheets Smith Wealth Management raised its position in Amgen by 1.6% in the 1st quarter. Sheets Smith Wealth Management now owns 13,000 shares of the medical research company’s stock worth $3,696,000 after purchasing an additional 210 shares during the last quarter. Bleakley Financial Group LLC raised its position in Amgen by 2.1% in the 1st quarter. Bleakley Financial Group LLC now owns 21,001 shares of the medical research company’s stock worth $5,971,000 after purchasing an additional 425 shares during the last quarter. ProShare Advisors LLC raised its position in Amgen by 10.9% in the 1st quarter. ProShare Advisors LLC now owns 711,683 shares of the medical research company’s stock worth $202,346,000 after purchasing an additional 69,693 shares during the last quarter. Finally, Avantax Advisory Services Inc. grew its holdings in Amgen by 10.0% during the 1st quarter. Avantax Advisory Services Inc. now owns 61,544 shares of the medical research company’s stock worth $17,498,000 after acquiring an additional 5,580 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on AMGN shares. Morgan Stanley lowered their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. BMO Capital Markets boosted their price target on shares of Amgen from $336.00 to $355.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. TD Cowen decreased their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Finally, Argus boosted their price target on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $312.63.

Amgen Price Performance

NASDAQ:AMGN traded down $0.13 during mid-day trading on Thursday, reaching $335.54. The stock had a trading volume of 260,219 shares, compared to its average volume of 2,679,764. The stock has a 50-day simple moving average of $311.02 and a two-hundred day simple moving average of $295.71. The stock has a market capitalization of $179.99 billion, a PE ratio of 47.95, a P/E/G ratio of 3.01 and a beta of 0.58. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. Amgen Inc. has a 12 month low of $228.21 and a 12 month high of $337.01.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period last year, the firm posted $3.98 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 19.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.